RXI PHARMACEUTICALS CORPORATION

Company

SELLAS Life Sciences Group, Inc.

Filed

April 23, 2009

Period of Report

June 5, 2009

Accession Number

0000950135-09-003035

A DEF 14A is a proxy statement sent to shareholders before an annual meeting. It covers executive compensation, board elections, and shareholder votes. Learn more about DEF 14A filings →